Compare AGX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | TARS |
|---|---|---|
| Founded | 1961 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | AGX | TARS |
|---|---|---|
| Price | $325.04 | $81.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $321.00 | $76.56 |
| AVG Volume (30 Days) | 445.6K | ★ 483.9K |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 76.74 | N/A |
| EPS | ★ 8.49 | N/A |
| Revenue | ★ $915,030,000.00 | $366,100,000.00 |
| Revenue This Year | $11.43 | $147.24 |
| Revenue Next Year | $18.27 | $53.11 |
| P/E Ratio | $38.33 | ★ N/A |
| Revenue Growth | 13.49 | ★ 182.44 |
| 52 Week Low | $101.02 | $38.51 |
| 52 Week High | $399.30 | $85.25 |
| Indicator | AGX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 58.62 |
| Support Level | $290.10 | $77.14 |
| Resistance Level | $329.59 | $83.34 |
| Average True Range (ATR) | 20.58 | 2.96 |
| MACD | -4.56 | -0.67 |
| Stochastic Oscillator | 53.15 | 49.23 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.